We would love for you to become a part of our community. Join our Discord to connect with us and other members!

Ticker
BSLN.SW

Price
41.35
Stock movement down
-0.25 (-0.60%)
Company name
Basilea Pharmaceutica AG
Exchange
(SW
,
Currency
CHF
)
Sector
Healthcare >
Biotechnology
Markedsverdi
501.21M
Ent verdi
610.12M
Pris/omsetning
2.14
Pris/bok
29.86
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
117.97%
Etterfølgende P/E
16.07
Fremtidig P/E
11.55
PEG
-
EPS-vekst
-
1 års avkastning
17.81%
3 års avkastning
-0.60%
5 års avkastning
-3.16%
10 års avkastning
-7.79%
Sist oppdatert: 2024-12-21

UTBYTTE

BSLN.SW betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E16.07
Pris til OCF15.58
Pris til FCF16.35
Pris til EBITDA14.77
EV i forhold til EBITDA17.98

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning2.14
Pris til bok29.86
EV i forhold til salg2.61

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall12.12M
EPS (TTM)2.26
FCF per aksje (TTM)2.22

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)233.93M
Bruttofortjeneste (TTM)155.42M
Driftsinntekter (TTM)28.46M
Netto inntekt (TTM)31.19M
EPS (TTM)2.26
EPS (1 år fremover)3.58

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)66.44%
Driftsmargin (TTM)12.17%
Fortjenestemargin (TTM)13.33%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter62.96M
Netto fordringer28.08M
Samlede omløpsmidler155.01M
Goodwill0.00
Immaterielle eiendeler473.00K
Eiendom, anlegg og utstyr0.00
Sum eiendeler188.66M
Leverandørgjeld11.47M
Kortsiktig/nåværende langsiktig gjeld112.45M
Sum kortsiktig gjeld37.78M
Sum gjeld171.88M
Aksjonærenes egenkapital16.79M
Netto varige driftsmidler0.00

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)32.16M
Kapitalutgifter (TTM)1.50M
Fri kontantstrøm (TTM)30.66M
Utbetalt utbytte (TTM)36.17M

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning185.80%
Avkastning på eiendeler16.53%
Avkastning på investert kapital165.47%
Kontantavkastning på investert kapital162.69%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning41.60
Daglig høy41.60
Daglig lav40.60
Daglig volum21K
Tidenes høyeste282.25
1 år analytikerestimat81.62
Beta0.74
EPS (TTM)2.26
Utbytte per aksje-
Ex-div dato11 Apr 2013
Neste dato for resultatpresentasjon11 Feb 2025

Nedsidepotensial

Loading...
Nedsidepotensial-data
BSLN.SWS&P500
Nåværende prisfall fra toppnotering-85.35%-2.74%
Høyeste prisfall-89.76%-56.47%
Dato for høyeste fall23 Nov 20119 Mar 2009
Gj.snittlig fall fra topp-63.49%-11.13%
Gj.snittlig tid til ny topp71 days12 days
Maks tid til ny topp4457 days1805 days
SELSKAPSOPPLYSNINGER
BSLN.SW (Basilea Pharmaceutica AG) company logo
Markedsverdi
501.21M
Markedsverdi kategori
Small-cap
Beskrivelse
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
Ansatte
156
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Land
Switzerland
By
Aksjetype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 16, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting...
16. desember 2024
Allschwil, Switzerland, September 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacteri...
24. september 2024
Initial funding of USD 29 million to support development of Basilea’s clinical stage first-in-class antifungals, fosmanogepix and BAL2062Multi-year Other Transaction Agreement (OTA) allows for potenti...
19. september 2024
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September 6, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting...
6. september 2024
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 27, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting t...
27. august 2024
Allschwil, Switzerland, August 21, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial ...
21. august 2024
Basilea Pharmaceutica (BPMUF) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed...
20. august 2024
Continued success of Cresemba® with 16.6% growth of royalties to CHF 42.8 million Operating result of CHF 9.3 million, net profit of CHF 20.7 millionTotal revenue guidance increased by 7% to CHF ~196 ...
13. august 2024
Allschwil, Switzerland, June 20, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial an...
20. juni 2024
If you are looking for stocks that are well positioned to maintain their recent uptrend, Basilea Pharmaceutica (BPMUF) could be a great choice. It is one of the several stocks that passed through our ...
21. mai 2024
Neste side